×
About 1,073 results

ALLMedicine™ Acute Graft Versus Host Disease Center

Research & Reviews  268 results

Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell a...
https://doi.org/10.1080/10428194.2022.2142054
Leukemia & Lymphoma; McClelland J, Wong E et. al.

Nov 12th, 2022 - Cyclosporine is an immunosuppressive agent to prevent acute graft versus host disease (GVHD) in patients undergoing a stem cell allograft. It has a narrow therapeutic range, and its metabolism can be affected by posaconazole, commonly used as anti...

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
https://clinicaltrials.gov/ct2/show/NCT04144036

Oct 10th, 2022 - Eligible patients will receive Neihulizumab weekly, for up to four doses. Responding patients, and patients with stable disease should receive all four weekly doses. Patients with skin only disease that clinically progresses by one stage (e.g, fro...

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
https://clinicaltrials.gov/ct2/show/NCT04281199

Oct 10th, 2022 - PRIMARY OBJECTIVES: I. To test whether the investigators can achieve a mean lung dose of < 8 Gy and still treat the total body at a minimum of 85% prescribed dose in patients undergoing allogeneic hematopoietic stem cell transplantation who are el...

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
https://clinicaltrials.gov/ct2/show/NCT05263999

Oct 3rd, 2022 - This study will enroll 200 subjects at approximately 125 sites globally. Subjects will be randomized in a 1:1 ratio to active or placebo and will receive a total of 7 doses administered intravenously approximately every 2 weeks. The study follows ...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  135 results

TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
https://clinicaltrials.gov/ct2/show/NCT04281199

Oct 10th, 2022 - PRIMARY OBJECTIVES: I. To test whether the investigators can achieve a mean lung dose of < 8 Gy and still treat the total body at a minimum of 85% prescribed dose in patients undergoing allogeneic hematopoietic stem cell transplantation who are el...

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
https://clinicaltrials.gov/ct2/show/NCT04144036

Oct 10th, 2022 - Eligible patients will receive Neihulizumab weekly, for up to four doses. Responding patients, and patients with stable disease should receive all four weekly doses. Patients with skin only disease that clinically progresses by one stage (e.g, fro...

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
https://clinicaltrials.gov/ct2/show/NCT05263999

Oct 3rd, 2022 - This study will enroll 200 subjects at approximately 125 sites globally. Subjects will be randomized in a 1:1 ratio to active or placebo and will receive a total of 7 doses administered intravenously approximately every 2 weeks. The study follows ...

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
https://clinicaltrials.gov/ct2/show/NCT03333486

Sep 16th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the rate of relapse, defined as recurrence of underlying disease or progression of underlying disease, at 1 year in patients who receive haploidentical peripheral blood stem cells (PBSCs) after reduced intensity ...

see more →

News  24 results

Overview of Therapy for Steroid-Refractory Acute Graft Versus Host Disease
https://www.onclive.com/view/overview-of-therapy-for-steroid-refractory-acute-graft-versus-host-disease

Aug 15th, 2022 - Transcript: Corey Cutler, MD, MPH, FRCPC: Given a patient with acute graft-vs-host disease in front of us, we do have to treat these patients. GVHD [graft-vs-host disease] if left untreated, progresses and ultimately is fatal in the absence of a ...

Investigators Seek to Push Combination Therapy to the Front-line Treatment of aGVHD
https://www.onclive.com/view/investigators-seek-to-push-combination-therapy-to-the-front-line-treatment-of-agvhd

May 27th, 2022 - High-dose systemic steroid administration has limited durability for patients who develop acute graft-vs-host disease (aGVHD). Novel agents seek to improve and expand the efficacy of the current standard of care for patients, specifically those wi...

Emerging Treatment Strategies for Chronic GVHD
https://www.onclive.com/view/emerging-treatment-strategies-for-chronic-gvhd

May 16th, 2022 - Transcript: Yi-Bin Chen, MD: As we conduct more trials for the treatment of chronic graft-versus-host disease [GVHD], by the time it's diagnosed there's a certain amount of fixed organ damage, and that's what I tell my patients. When I see them, ...

Itolizumab Under Further Investigation in EQUATOR Trial as Frontline aGVHD Treatment
https://www.onclive.com/view/itolizumab-under-further-investigation-in-equator-trial-as-frontline-agvhd-treatment

Apr 1st, 2022 - The addition of itolizumab to standard-of-care (SOC) corticosteroids vs placebo will be evaluated in patients with acute graft-versus-host disease (aGVHD), as part of the phase 3 EQUATOR trial (NCT05263999), according to John Koreth, MBBS, DPhil, ...

First FDA Approval for Prevention of Acute Graft-vs-Host Disease
https://www.medpagetoday.com/hematologyoncology/othercancers/96220

Dec 15th, 2021 - The FDA granted a first-ever approval of a treatment to prevent acute graft-versus-host disease (aGVHD) in patients undergoing bone marrow or stem-cell transplantation. The approval allows use of abatacept (Orencia) in combination with certain imm...

see more →

Patient Education  1 results see all →